and provide it under GMP conditions for innovators engaged in clinical research." Macrocyclics is an exhibitor at the 2025 SNMMI Annual Meeting, located in New Orleans, LA from June 21 to June 24. Ratio will also have representatives in attendance...
were alive. These results were shared today during an oral presentation at the 30th European Hematology Association (EHA) 2025 Congress. The safety profile of this combination therapy showed cytokine release syndrome (CRS) being low grade and no...
also includes potential future indications. Avanzanite is rapidly scaling its operations, having tripled its revenue in Q1 2025 year-over-year, with two rare disease medicines already on the market. Over the next 12 months, the company will expand...
rhCollagen for tissue regeneration and medical aesthetics, today announced financial results for the first quarter of 2025 and provided a corporate update. Yehiel Tal, CollPlant's Chief Executive Officer commented, "While advancing our core...
Doxycycline for Injection, USP had U.S. sales of approximately $47 million for the twelve months ending in March 2025.1 Indications: Doxycycline for Injection, USP is indicated for the treatment of infections proven or strongly suspected to be...
key global markets. The drug received FDA approval in September 2024 and has been available in the U.S. since March 2025. Otulfi (ustekinumab-aauz) is a human monoclonal antibody that targets the cytokines interleukin-12 and interleukin-23, which...
in the U.S. A Phase 2 clinical trial of LTI-03 for the treatment of idiopathic pulmonary fibrosis was initiated in May 2025. Rein's second product candidate, LTI-01, is a proenzyme that has completed Phase 1b and Phase 2a clinical trials for the...
autonomy for both Spain and the European Union. The Ministry provisionally awarded €53.2 million in funding on May 5, 2025, to support 37 breakthrough projects across 11 autonomous communities. INBRAIN’s project was one of several selected for...
immunoregulatory therapeutics for inflammatory and autoimmune diseases, will present at Digestive Disease Week 2025 first ever head-to-head clinical and translational results from two studies for omilancor, a Phase 3 first-in-class LANCL2 agonist...
comprises capabilities for low- to medium-volume DDC assembly and packaging. Both facilities will be GMP ready in fall 2025. In Europe, PCI recently acquired a packaging and device assembly facility in Dundalk, Ireland, which provides...
and the UK Government, including Innovate UK and the NIHR. The first participant was dosed in the trial on the 15th April 2025 and is expected to be completed in Q3 2025. Stablepharma’s next-generation technology platform StablevaX™ reformulates...
2b study in patients with moderate-to-severely active UC (XENITH-UC), with the expected study start in the second half of 2025. Lead selection for Xencor’s XmAb TL1A x IL23p19 bispecific antibody continues to advance. New in vitro studies show that...
more than 20 sites across the United States and Europe, with patient enrollment expected to begin in the fourth quarter of 2025. The trial’s primary endpoint, hepatic progression-free survival, is anticipated to be announced by the end of 2028,...
Association (AUA) Annual Meeting, the largest gathering of urologists in the world, which takes place April 26-29, 2025. "We know that healthcare providers value hands-on approaches to learning, and technology like the Spatial Computing Injection...
daily use per toe, making it an effortless addition to any self-care or health routine. What Makes BioClear Stand Out in 2025? The BioClear device is aligned with current health tech trends, combining smart wellness innovation with...
for chronic eye diseases, announced the appointment of Beth Marsh as Chief Commercial Officer, effective April 28, 2025. In this role, Beth will lead the commercial organization, including preparing for the U.S. launch of ENCELTOTM (revakinagene...
System to expand access to the limited supply of donor organs and improve post-transplant outcomes. As of April 2025, nearly 90,700 people are on the kidney transplant waiting list in the U.S., representing 86% of the national transplant list. In...
undergoing autologous stem cell transplant (ASCT; NCT05561751). Clinical trial results for this study are expected in Q4 2025. Current Evaluating Potential Indication Expansions – In addition to AML and MM, Exicure is evaluating a range of...
serious adverse outcomes in pregnant women with APS and their babies. The study results were published online on April 10, 2025 in Annals of the Rheumatic Diseases. “The IMPACT study represents a bold and very successful partnership over many years...
clinics in Australia. Pykus intends to submit an Investigational Device Exemption (IDE) application to the FDA in Q4 2025 for a multicenter U.S. pivotal trial, pending financing and regulatory discussions. The Company plans to meet with FDA in Q3...
